Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Stocks, Fed and market
Stock Market Today: Dow climbs 100 points after Fed's historic rate cut of 50 basis points
U.S. stocks rose after the Federal Reserve lowered its benchmark interest rates by 50 basis points to a range of 4.75% to 5%. That was the first rate cut in over four years that marked the beginning of a monetary-easing cycle in the world's largest economy.
Morgan Stanley lays out the stock market's best-case scenario for this week's Fed decision — and 2 areas to buy after the cut
Stocks will get a boost if the Fed is able to cut interest rates by 50 bps without spurring growth fears, Morgan Stanley says.
Stock market today: World markets shoot higher after Fed's first rate cut in over 4 years
Markets in Europe and Asia have shot higher after the Federal Reserve kicked off its efforts to prevent a recession in the U.S. with a bigger-than-usual cut to interest rates
2h
Stock market today: Dow surges 500 points as Fed-fueled stocks set sights on records
The S&P 500 ( ^GSPC) climbed roughly 1.7%, while the Dow Jones Industrial Average ( ^IXIC) rose more than 500 points, with ...
2d
Stock Market Today: Dow scores new record close as expectations grow for jumbo rate cut
U.S. stocks ended mixed on Monday, as traders’ expectations for the Federal Reserve to deliver a 50-basis-point rate cut on ...
5d
on MSN
Stock market today: Wall Street’s best week of 2024 closes with indexes near their records
Asian stocks are mixed after U.S. stocks pulled closer to their records on economic reports that came in close to ...
5d
on MSN
Stock market today: S&P 500 notches 5-day streak of gains ahead of next week's Fed meeting
Odds of a 50 basis point interest rate cut next week have surged as investors worry about a slowdown in the job market.
6d
Why Summit Therapeutics Skyrocketed 123% This Week
Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
NIFTY 50
Fed
Wall Street
Dow Jones Industrial Average
Artificial intelligence
Feedback